What Is ARA-290?

1. How does ARA-290 work, and how is it different from EPO?

EPO stimulates red blood cell production. Researchers also found tissue-protective effects and tried to separate those activities. In Brines and colleagues’ 2008 experiments, small peptides modeled on EPO’s three-dimensional structure retained protective activity in laboratory and animal models without stimulating red blood cell production.

ARA-290 comes from that work. It mimics a surface region of EPO; it is not the whole hormone. Later clinical papers describe its target as the innate repair receptor, a complex containing an EPO receptor subunit and CD131. The proposed signaling reduces inflammatory injury and supports cell survival and repair. Culver et al., 2017.

“Nonerythropoietic” means it does not stimulate red blood cell production. That explains the design goal. It does not establish that the compound is harmless, that all injured tissues respond, or that a healthy athlete gains endurance. ARA-290’s human trials primarily enrolled people with disease and impaired nerve function.

2. Why study ARA-290 for small fiber neuropathy?

Small nerve fibers carry pain and temperature signals and contribute to automatic functions such as sweating. Damage can produce burning feet, altered sensation and pain from contact that would normally be comfortable. Sarcoidosis, an inflammatory disease, and diabetes can both involve these fibers.

Researchers can image small nerves in the cornea, the clear front surface of the eye, using corneal confocal microscopy. They can also examine nerve fibers in a skin biopsy. Those methods allow a trial to ask whether nerve structure changes alongside symptoms. The 2013 sarcoidosis study used both.

A corneal measurement is a surrogate endpoint: a biological sign researchers use to investigate a potential treatment effect. An increase cannot, by itself, establish that damaged nerves throughout the body have recovered. Skin findings, sensation, pain, function and durability still need separate assessment.

3. What do the human ARA-290 trials show?

The principal neuropathy trials were small and generally administered treatment for four weeks. Their populations and measurements differ, so pooling them into one “nerve repair success rate” would be misleading.

Several investigators in this research program disclosed employment, consulting, research support or patent interests connected to Araim Pharmaceuticals. Those relationships are reported in the papers and make independent replication particularly useful.

The 64-person trial: what “nerve regeneration” measured

The Phase 2b trial compared 1, 4 and 8 mg daily with placebo. Its primary endpoint was the change in corneal nerve fiber area after 28 days. The placebo-adjusted increase in the 4 mg group was 697 square micrometers, with a 95% confidence interval of 159 to 1,236 and a p-value of 0.012. The other two doses did not reach statistical significance on that endpoint.

The researchers also detected more GAP-43-positive nerve fibers in skin in the 4 mg group. GAP-43 is associated with newly growing or regenerating fibers. Standard skin nerve-fiber density did not show a corresponding significant change. Different staining methods measured different features of the tissue.

Pain improved in every group, including placebo. Among participants starting with moderate-to-severe pain, the 4 mg group’s placebo-adjusted advantage was about one point, but the confidence interval crossed zero and the p-value was 0.157. The walking-distance comparison also missed statistical significance. These results support further investigation of nerve repair while leaving the size and reliability of a patient-perceived benefit unresolved.

4. Does ARA-290 improve blood sugar or promote longevity?

The diabetes trial included complete serial HbA1c measurements for 42 participants. By day 56, mean HbA1c had fallen by 0.21 percentage points in the ARA-290 group and risen by 0.21 points in the placebo group. Participants generally had well-controlled diabetes at baseline and continued their existing medications.

That is an early metabolic finding in people with diabetes and painful neuropathy. It does not establish weight loss, an advantage over GLP-1 treatments, or a benefit from adding ARA-290 to tirzepatide. The study did not test those questions.

Longevity interest comes partly from Winicki and colleagues’ aging-rat study. Rats entered at 18 months of age and received ARA-290 or saline during a 15-month experiment. Treated animals had favorable changes in cardiac inflammation, heart function and frailty measures. Median lifespan and overall survival did not differ significantly between groups (p = 0.182).

The paper supports research into age-related function. It supplies neither a demonstrated lifespan extension in rats nor evidence of longer life in humans.

5. ARA-290 dosage and half-life: what was actually studied?

Published regimens included 2 mg intravenously three times weekly for four weeks in the 2012 pilot and 4 mg subcutaneously daily for 28 days in the sarcoidosis and diabetes studies. The later dose-ranging trial compared 1, 4 and 8 mg daily. These describe monitored research exposures; they do not establish an approved dose, maintenance schedule or self-treatment cycle.

The diabetes paper reports healthy-volunteer pharmacokinetic findings of a terminal plasma half-life around 20 minutes after a 4 mg subcutaneous dose. Earlier IV work describes clearance over a few minutes. Route and measurement context explain why different half-life figures appear online.

Blood concentration and biological response follow different timelines. A brief exposure can initiate signaling that continues after the peptide clears. Conversely, a short half-life does not establish a need for frequent injections. A half-life model estimates exposure from its inputs; it cannot predict nerve growth or identify an effective schedule.

The human trials discussed here also cannot validate oral capsules or nasal sprays. Their bioavailability and clinical effects would need testing with the actual formulation.

6. ARA-290 side effects and safety

“No side effects” is an inaccurate description of the trial record. In the 2017 Phase 2b paper, frequently reported adverse events included injection-site pain, diarrhea, fatigue, headache and nausea. Events occurred across treatment and placebo groups without a clear dose relationship, so the list does not establish that ARA-290 caused every event.

The same paper reports suicidal ideation in one participant in the 8 mg group, classified as possibly related to treatment. Serious events in two participants in the 1 mg group were considered unrelated. A single event cannot establish causation or a dependable risk rate, but it belongs in a safety discussion.

The diabetes study reported four serious adverse events in the active-treatment arm, two judged possibly related. One participant stopped treatment after kidney function worsened in the setting of an increased diuretic dose. Another developed severe cellulitis after dosing ended and subsequently had a fatal myocardial infarction; the safety committee judged the event unrelated to ARA-290.

These reports need context, including underlying disease and other medications. They also prevent describing the evidence as risk-free. Small samples and short exposure leave substantial uncertainty about uncommon harms, repeated cycles and drug combinations. A commercially sold research vial also cannot inherit the identity, sterility and manufacturing controls of a clinical-trial preparation from its label alone.

7. ARA-290 vs BPC-157, TB-500 and peptide stacks

ARA-290’s human research focuses on small fiber neuropathy. BPC-157 and TB-500 attract interest in tendon and soft-tissue recovery, but their evidence differs in molecule, condition, route and study quality. None of the ARA-290 trials above compares these compounds head to head.

Calling a combination a “nerve repair stack” does not establish an additive benefit. The cited trials do not test ARA-290 with BPC-157, TB-500 or KPV, and they provide no validated interaction profile for those combinations.

For anyone tracking burning pain, sleep or exercise tolerance, a symptom log can document when something changed. It cannot show that nerve fibers regrew. If medication, training load and several peptides change together, the log also cannot isolate which change caused the result. Objective nerve testing requires clinical assessment and an appropriate measurement method.

8. Is ARA-290 approved, and what happened to development?

ARA-290 remains investigational, with no FDA-approved medical use as of September 22, 2026. A search of the FDA approved-drug database found no cibinetide approval. The EMA’s orphan designation record concerns prevention of graft loss in pancreatic islet transplantation. The agency explicitly distinguishes orphan designation from authorization to market a medicine.

The sarcoidosis Phase 2 trial record lists completion. A later-posted diabetic macular edema record lists termination because study drug expired and no replacement was available. Its posting date does not mean a new trial began then: the recorded study ran in 2016–2017.

The corresponding 2020 paper by Lois and colleagues enrolled nine people, eight of whom completed the study. After 12 weeks, average visual acuity and central retinal thickness had not improved. It was an uncontrolled pilot, so improvements in selected participants could not establish effectiveness.

For future ARA-290 research, the unresolved clinical questions are whether structural nerve changes produce reproducible relief, better daily function and lasting benefit, and what harms emerge with longer exposure. A larger controlled trial measuring those outcomes would be more informative than another short report of improved corneal images.

9. ARA-290 FAQ

• Is ARA-290 the same as cibinetide?

  Yes. Cibinetide is the name used for the investigational peptide also called ARA-290, ARA 290 or ARA290. Papers also describe it as pyroglutamate helix B surface peptide, or pHBSP.

• Does ARA-290 regenerate nerves?

  Small human trials reported increased corneal nerve measurements, and a 2017 study found a change in a skin marker of regenerating fibers. These findings support further research but do not establish complete nerve repair, durable pain relief or recovery from every type of nerve injury.

• What ARA-290 dosage was used in human studies?

  Several trials studied 4 mg subcutaneously daily for 28 days; a Phase 2b trial compared 1, 4 and 8 mg with placebo. An earlier pilot used 2 mg intravenously three times weekly for four weeks. These were research regimens, not approved doses or validated self-treatment instructions.

• What is the half-life of ARA-290?

  The diabetes trial paper reports a terminal plasma half-life of about 20 minutes after a 4 mg subcutaneous dose in healthy-volunteer pharmacokinetic work. Earlier IV research describes a half-life of a few minutes. Clearance from blood does not measure how long a biological effect lasts.

• What are the side effects of ARA-290?

  The Phase 2b paper lists injection-site pain, diarrhea, fatigue, headache and nausea among the most frequent adverse events. It also reports suicidal ideation in one participant in the 8 mg group, considered possibly related. The studies are too small to estimate uncommon risks reliably.

• Does ARA-290 increase red blood cells like EPO?

  ARA-290 was designed to retain tissue-protective activity without EPO's red-blood-cell stimulation. That design does not prove an absence of other risks, and human research has not established an endurance benefit.

• Is ARA-290 better than BPC-157 for nerve damage?

  ARA-290 has placebo-controlled human studies focused on small fiber neuropathy. There is no reliable human head-to-head comparison establishing superiority to BPC-157, or a benefit from combining them.

• Does ARA-290 extend lifespan?

  Human lifespan benefits have not been established. A 15-month study in aging rats reported improvements in cardiac function and frailty, but median lifespan and overall survival did not differ significantly between treatment groups.

• Is ARA-290 FDA-approved?

  ARA-290 remains investigational and has no FDA-approved medical use as of September 22, 2026. Orphan drug designation supports development for a rare condition; it does not authorize marketing or establish effectiveness.

10. Sources